Biodesix has closed on a $12 million extension to its Series D financing. The new capital will support commercialization activities for VeriStrat.
Results from two phase II advanced lung cancer trials will be presented at the upcoming 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.
Biodesix announced the appointment of Dominic Spinella, Ph.D., as Vice President of Clinical Development & Medical Affairs.
The first presentation of data resulting from a corporate partnership to explore development of a new diagnostic test based on Biodesix’ technology.
Biodesix’ Paul Beresford will join industry veterans on a panel discussing the recipe for the successful commercialization of personalized medicine.
VeriStrat test was able to identify patients likely to have better and worse survival outcomes when treated with the combination therapy.
Biodesix today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix’ VeriStrat® test in a Phase 3 (NSCLC).
Biodesix, Inc., today announced the relocation of their corporate headquarters from Broomfield, Colorado to Boulder, Colorado.
Biodesix announced the issuance of three additional patents. Two which provide intellectual property protection and the other for Veristrat.
Veristrat can be used to identify a group of patients with worse progression-free (PFS) when treated with Femera alone, independent of Her2 status.